Cantel Medical (NYSE:CMD) Lowered to Neutral at Sidoti


Share on StockTwits

Cantel Medical (NYSE:CMD) was downgraded by investment analysts at Sidoti from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, The Fly reports.

Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Cantel Medical from a “hold” rating to a “strong-buy” rating and set a $88.00 target price on the stock in a research note on Monday, December 21st. CJS Securities started coverage on shares of Cantel Medical in a report on Friday, October 23rd. They issued an “outperform” rating and a $70.00 target price for the company. Finally, BidaskClub upgraded shares of Cantel Medical from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Cantel Medical currently has an average rating of “Buy” and an average target price of $74.80.

Shares of CMD opened at $82.40 on Tuesday. The business’s 50-day moving average is $78.90 and its two-hundred day moving average is $60.65. The company has a market capitalization of $3.48 billion, a P/E ratio of 98.10, a P/E/G ratio of 1.67 and a beta of 1.54. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.31 and a current ratio of 3.13. Cantel Medical has a fifty-two week low of $20.81 and a fifty-two week high of $89.10.

Cantel Medical (NYSE:CMD) last posted its earnings results on Tuesday, December 8th. The company reported $0.90 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.54. Cantel Medical had a return on equity of 11.19% and a net margin of 3.38%. The firm had revenue of $297.03 million for the quarter, compared to analysts’ expectations of $292.50 million. Analysts forecast that Cantel Medical will post 2.6 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Emerald Mutual Fund Advisers Trust grew its position in shares of Cantel Medical by 28.9% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 2,426 shares of the company’s stock valued at $107,000 after purchasing an additional 544 shares during the last quarter. Emerald Advisers LLC raised its stake in Cantel Medical by 16.5% during the third quarter. Emerald Advisers LLC now owns 9,814 shares of the company’s stock worth $431,000 after purchasing an additional 1,391 shares during the period. Dupont Capital Management Corp raised its stake in Cantel Medical by 271.1% during the third quarter. Dupont Capital Management Corp now owns 15,723 shares of the company’s stock worth $691,000 after purchasing an additional 11,486 shares during the period. Comerica Bank raised its stake in Cantel Medical by 38.1% during the third quarter. Comerica Bank now owns 73,329 shares of the company’s stock worth $3,818,000 after purchasing an additional 20,221 shares during the period. Finally, Sciencast Management LP purchased a new position in Cantel Medical during the third quarter worth approximately $376,000. Institutional investors own 95.01% of the company’s stock.

About Cantel Medical

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.

Featured Article: Asset Allocation and Your Retirement

The Fly

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.